Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...
Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from ...
Keeping up with scientific advances and practice changes can be one the biggest challenges in managing a complex disease like multiple sclerosis (MS). The Consortium of Multiple Sclerosis Centers ...
Multiple sclerosis (MS) is an insidious disease. Patients suffer because their immune system is attacking their own nerve fibres, which inhibits the transmission of nerve signals. People with MS ...
The symptoms of MS vary widely in location and severity among individuals. Common symptoms include fatigue, numbness, focal weakness, visual changes such as unilateral visual loss and diplopia, ...
A blood-based biomarker assay for multiple sclerosis (MS) disease activity provides actionable insights that supplement standard MS evaluations, especially for treatment initiation and de-escalation ...
NEW YORK, Sept. 11, 2025 /PRNewswire/ -- Great Place To Work® and Fortune magazine have selected the International Multiple Sclerosis Management Practice (IMSMP) for the 2025 Fortune Best Workplaces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback